High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
复制标题
DOI：
10.1186/1746-1596-6-91
复制
发表时间：
2011-09-28
影响因子：
2.6
通讯作者：
Jirström K
中科院分区：
文献类型：
--
作者：
Jonsson L;Gaber A;Ulmert D;Uhlén M;Bjartell A;Jirström K
先前已经发现RNA结合蛋白RBM 3的高表达与乳腺癌、卵巢癌、恶性黑色素瘤和结直肠癌的良好预后相关。本研究的目的是研究免疫组化RBM 3表达对前列腺癌预后的影响。采用免疫组织化学方法检测了88例因局部疾病行根治性前列腺切除术患者的良性和恶性前列腺标本的组织微阵列中RBM 3的表达。虽然在良性前列腺上皮中很少表达，但发现RBM 3在前列腺上皮内瘤变中上调，并且在浸润性前列腺癌中以各种分数和强度存在。高核RBM 3表达与至生化复发（BCR）（HR 0.56，95% CI：0.34-0.93，p = 0.024）和临床进展（HR 0.09，95% CI：0.01-0.71，p = 0.021）的时间延长显著相关。这些相关性在多变量分析中仍然显著，调整了术前血液PSA水平，病理Gleason评分和是否存在囊外扩张，精囊浸润和手术切缘阳性（BCR的HR 0.41，95% CI：0.19-0.89，p = 0.024;临床进展的HR 0.06，95% CI：0.01-0.50，p = 0.009）。我们的研究结果表明，前列腺癌中RBM 3的高核表达与疾病进展的时间延长有关，因此是有利预后的潜在生物标志物。RBM 3对于前列腺癌患者的分类、治疗分层和随访的价值应在更大规模的研究中进一步验证。
High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer. Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial neoplasia and present in various fractions and intensities in invasive prostate cancer. High nuclear RBM3 expression was significantly associated with a prolonged time to biochemical recurrence (BCR) (HR 0.56, 95% CI: 0.34-0.93, p = 0.024) and clinical progression (HR 0.09, 95% CI: 0.01-0.71, p = 0.021). These associations remained significant in multivariate analysis, adjusted for preoperative PSA level in blood, pathological Gleason score and presence or absence of extracapsular extension, seminal vesicle invasion and positive surgical margin (HR 0.41, 95% CI: 0.19-0.89, p = 0.024 for BCR and HR 0.06, 95% CI: 0.01-0.50, p = 0.009 for clinical progression). Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3 for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in larger studies.
登录
查看更多内容
影响因子：
64.8
作者：
Bartkova, J;Horejsi, Z;Bartek, J
通讯作者：
Bartek, J
影响因子：
7.4
作者：
Jonsson L;Bergman J;Nodin B;Manjer J;Pontén F;Uhlén M;Jirström K
通讯作者：
Jirström K
影响因子：
158.5
作者：
Bill-Axelson, Anna;Holmberg, Lars;Johansson, Jan-Erik
通讯作者：
Johansson, Jan-Erik
影响因子：
3.6
作者：
Wellmann, Sven;Truss, Matthias;Buehrer, Christoph
通讯作者：
Buehrer, Christoph
影响因子：
7
作者：
Uhlén, M;Björling, E;Pontén, F
通讯作者：
Pontén, F